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EXTENDED ANTIDEPRESSANT MAINTENANCE
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Unipolar and bipolar depression are episodic, recurrent illnesses for the major-
ity of patients. Because each episode engenders considerable costs for patients,
families, and society, prevention of recurrences has high priority. Numerous
studies demonstrate that maintenance antidepressants or mood stabilizing
medications are efficacious in preventing recurrences. A review of mainte-
nance studies supports the view that all antidepressants perform significantly
better than placebo in preventing recurrences of depression—with the stipula-
tion that full antidepressant doses be employed. Earliest studies, conducted two
decades ago, evaluated tricyclics (TCAs), heterocyclics, and lithium, while re-
cent studies have focused on selective serotonin reuptake inhibitors (SSRIs).
Compliance is essential. Strategies for enhancing compliance include selection
of medications with reported safety and few side effects, education of patients
and families, referral to patient advocacy groups, and use of new technological
compliance aids. Preliminary data suggest that SSRIs are better tolerated than
TCAs; fewer patients discontinue these agents due to side effects. Selection cri-
teria for maintenance treatment have not been well determined, but three or
more prior episodes is recognized as a relatively strong indicator. Other clini-
cal or genetic criteria have also been suggested.
For various reasons, patients may discontinue medications, and when this
happens withdrawal phenomena may occur. Withdrawal effects are well docu-
mented for all antidepressants and can be profound with TCAs. After stopping
some SSRIs, a few withdrawal symptoms may have similarities with those fol-
lowing discontinuation of TCAs, but unique “CNS-like” effects are frequently
described, including brief recurrent episodes of dizziness, lightheadedness, ver-
tigo, electric shock-like sensations, and gait instability. These appear to be half-
life dependent, with agents with shorter half-lives having more discontinuation
symptoms. If antidepressant medications must be discontinued, a gradual taper
is preferable, perhaps extending three to six months or longer to prevent discon-
tinuation effects, enable adaptation at the receptor level and allow earlier rec-
ognition and treatment of recurrent depressive symptoms. Depression and
Anxiety, Volume 8, Supplement 1:43–53, 1998. © 1998 Wiley-Liss, Inc.
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LONGITUDINAL COURSE
OF DEPRESSION
Depression is an episodic, recurrent illness for the
majority of those afflicted. Estimates from longitudi-
nal assessments have shown that 50–95% of patients
with major depressive disorder (MDD) will experience
multiple episodes over their lifespans unless mainte-
nance treatment is provided (Angst et al., 1973; Frank
et al., 1990; Goodwin and Jamison, 1990; Greden,
1993; Grof et al., 1973; Kraepelin, 1921; Montgomery,
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1988; NIMH/NIH, 1985; Thase, 1990). Natural his-
tory assessments demonstrate that, for many, each suc-
cessive depressive episode tends to occur sooner, last
longer, intensify in severity, and perhaps become more
difficult to treat (Grof, 1973; Keller et al., 1982a,b;
Keller, 1983, 1985; Kraepelin, 1921; Post et al., 1986;
Post, 1992, 1994; Roy-Byme, 1985; Zis and Goodwin,
1979). Given these observations, maintenance treat-
ment of depression has been advocated for selected pa-
tients (Greden, 1993; Hirschfeld, 1994), and the
importance of extended maintenance has received pro-
gressively more attention during each passing year.
WHAT IS MAINTENANCE
TREATMENT?
For nosologic and conceptual reasons, treatment for
depression has been conceptualized to occur in three
phases (acute, continuation, and maintenance (Kupfer,
1991)) and the “5 R’s” (response, remission, relapse,
recovery, and recurrence) have been proposed as
points of change during treatment (Frank et al., 1991;
Kupfer, 1991). Such designations are a bit arbitrary
since the natural longitudinal course for most patients
tends to be irregular and unpredictable, with recur-
rences and relapses occurring at variable time intervals
after maintenance is discontinued. Thus, it can be ar-
gued that for many and, perhaps, most patients, true
“recovery” never occurs. While the designation of
phases provided helpful semantic standardization, this
review will not employ the terms “continuation treat-
ment” or “recovery” and will operationally define
maintenance treatment as including any and all treat-
ments that follow the resolution of the acute episode
and are intended to prevent reappearance of symp-
toms. It may be of any duration and even persist for
one’s lifetime, with its major objectives being preven-
tion of worsening of severity, overt relapses, or recur-
rence of MDD at any time in the future.
MAINTENANCE TREATMENT
OPTIONS
Most maintenance treatments are extensions of
treatments used for acute depressive episodes. A cat-
egorical list of options includes medications alone,
psychotherapy alone, medications plus psychotherapy,
and somatic treatments such as electroconvulsive
therapy (ECT) or phototherapy (APA, 1990; Beck et
al., 1979; Covi et al., 1974; Doogan and Caillard,
1992; Elkin et al., 1989; Frank et al., 1993; Jacobson et
al., 1991; Katon et al., 1992; Klerman et al., 1974;
Kupfer et al., 1992; Montgomery et al., 1988; Prien et
al., 1984; Rehm, 1979; Rush et al., 1977; Thase,
1990). This list of options is somewhat misleading,
however, since adequate data have been collected only
for medications or for the combination of antidepres-
sant medications plus psychotherapy. Too few con-
trolled studies have assessed psychotherapy alone, so-
matic interventions alone, or various other combina-
tions of treatments. This review will focus on extended
maintenance with antidepressant medications, the only




Over the past four decades, the antidepressant arma-
mentarium available to clinicians has grown steadily.
Prescribing changes have paralleled the increased
availability of options. Tricyclic and heterocyclic
agents dominated prescription patterns for almost
three decades, so it is understandable that most earlier
maintenance studies assessed these agents. Since the
introduction of fluoxetine one decade ago and the re-
lease of other SSRIs during subsequent years, these
agents have rapidly become first-line choices (Nemer-
off, 1994; Tollefson, 1993), largely due to their greater
tolerability, safety, ease of prescription, and fewer side
effects (these aspects are addressed elsewhere in this
special issue). Because SSRIs have only been widely
used for 5–10 years (depending on the agent), fewer
studies have evaluated their effectiveness. The SSRI





When seeking to assess the long-term effectiveness
of maintenance treatment, naturalistic data can be
misleading and interpretations risky. Greden (in press)
has suggested that studies used to determine effective-
ness of maintenance should minimally incorporate: 1)
a placebo control, 2) a treatment duration of 12 to 18
months (preferably longer), 3) adequate dosage, 4)
monitoring of compliance, and 5) control for con-
comitant treatments. Sadly, fewer than 25–30 studies
meet most of these criteria; impressively, virtually all
strongly support the superiority of maintenance anti-





Maintenance antidepressants prevent relapses in the
majority of patients over a long-term course. They are
the only interventions known to do so. This is a pro-
found observation, but despite its importance it has
not been widely incorporated into practice.
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Table 1 lists studies on maintenance antidepressants
with acceptable methodologic criteria. As stated, ear-
lier studies generally employed tricyclics or lithium as
the maintenance agents. Most were at the minimum
range of acceptable duration (12–18 months). Clinical
approximations are difficult, but an estimate from the
best studies suggests that about 75% of patients re-
main euthymic for 12–36 months or longer, if ad-
equate maintenance treatment is provided, whereas
50–75% of those with multiple prior episodes relapse
if maintenance is discontinued. A conservative state-
ment from all studies is that recurrence rates tend to
be at least twice as large for those crossed over to pla-
cebo as for those maintained on antidepressants, but
the differences are likely to be greater since adequate
maintenance doses were not always used in earlier
TABLE 1. Efficacy of antidepressant maintenance vs. placebo in prevention of unipolar depression, percent relapse*
Reference Medication Placebo Rx Significance
Newer Agents
SSRIs
Bjork, 1983 Zimelidine 84 32 .001
Montgomery et al., 1988 Fluoxetine 57 26 .001
Jakovljevic and Mewett, 1991 Paroxetine 23 14 N.S.
Doogan and Caillard, 1992 Sertraline 46 13 .001
Claghorn and Feighner, 1993 Paroxetine 25 15 N/A
Montgomery and Dunbar, 1993 Paroxetine 30 14 .05
Montgomery et al., 1993 Citalopram 31 10 .05
Kocsis et al., 1997 Sertraline N/A 83 N/A
Wilson et al., 1997 Sertraline abstract only, no results
Others
Anton et al., 1994 Nefazodone 25 9 .01
Feiger et al., 1996,1997 Nefazodone 14 1.6 .01
Entsuah et al., 1996 Venlafaxine 34 20 <.03
Montgomery and Kremer, 1997 Mirtazapine 35 8 .0001
Older Agents
TCAs
Prien et al., 1973 Imipramine 85 29 .01
Coppen et al., 1978 Amitryptyline 31 0 .01
Kane et al., 1982 Imipramine 100 67 N.S.
Glen et al., 1984 Amitryptyline 88 43 .05
Prien et al., 1984 Imipramine 71 44 .05
Frank et al., 1990 Imipramine 78 21 .001
Jakovljevic and Mewett, 1991 Imipramine 23 12 .05
Rouillon et al., 1991 Maprotoline 32 16 .01
Kupfer et al., 1992 Imipramine 67 9 .006
Claghorn and Feighner, 1993 Imipramine 25 4 N/A
Anton et al., 1994 Nefazodone 25 8 .05
Montgomery and Kremer, 1997 Mirtazapine 35 21 .002
MAOIs
Georgotas et al., 1989 Phenelzine 65 13 .05
Robinson et al., 1991 Phenelzine 75 10 .001
Lithium
Prien et al., 1973 Lithium 85 4 .05
Prien et al., 1973 Lithium 71 57 .05
Schou, 1979 Lithium 84 29 .001
Kane et al., 1992 Lithium 100 29 .001
Glen et al., 1984 Lithium 88 42 .05
*Time periods for relapse/recurrence vary considerably: several studies are 9 to 12 months from starting placebo, most are approximately 12 months, several are
12 to 24 months, and two are longer than 36 months (Frank et al., 1990; Kupfer et al., 1992).
studies (discussed below). The longest and best pla-
cebo-controlled investigation was a three-year study
by Frank et al. (1990), with a subsequent two-year ex-
tension for some subjects by these same investigators
(Kupfer et al., 1992). These two reports strongly sub-
stantiated the effectiveness of imipramine, revealing
that this TCA was successful in preventing recur-
rences of depression in almost eight of every ten pa-
tients, even after three years.
Published reports to date about SSRI maintenance
therapy include three one-year studies, one of fluoxe-
tine (Montgomery et al., 1988), one of paroxetine
(Montgomery and Dunbar, 1993), and one of sertra-
line (Doogan and Caillard, 1992). All three SSRIs
were shown to perform significantly better then pla-
cebo in preventing recurrences of depression. Kocsis
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et al. (1997) presented preliminary findings on a two-
year maintenance study using sertraline, employing
the terminology recommended by Kupfer (1991).
Eighty-three percent of 22 sertraline responders
maintained their response during a “continuation
phase.” Results are pending for the “maintenance
phase.” Entsuah et al. (1996) evaluated venlafaxine and
concluded it also is more effective than placebo (P =
0.022) in maintaining the initial clinical response, but
limitations of the study included a low relapse rate for
placebo and a low completion rate. Anton et al. (1994)
demonstrated nefazodone as more effective than
placebo (P = 0.01). Finally, Feiger et al. (1996) dem-
onstrated that nefazodone was more effective than pla-
cebo in sustaining euthymia, but the placebo group in
this study also had a low relapse rate and the study was
only nine months in duration. The importance of rela-
tively complete resolution of symptoms is suggested
by Judd’s (1997) observation that patients who still
suffer subsyndromal depressive symptoms relapse 5.5
times more rapidly than patients who had no residual
depressive symptoms.
Montgomery (1991) argues that “the evidence in fa-
vor of SSRIs as a group is now stronger than the evi-
dence for the tricyclic antidepressants” because of the
variability in study quality among the earlier genera-
tion of studies. Silverstone (1992) maintained, how-
ever, that the newer antidepressants have not yet been
proven more effective than the standard TCAs. Only
“head-to-head” comparisons with adequate samples of
patients with prior documented recurrences will truly
answer this debate, and they must incorporate adequate
treatment duration and adequate dosage. In essence,
there is a dire need for longer-term, well-controlled
studies with both older and newer agents and with aug-
menting strategies.
Meanwhile, a conservative summary suggests that
while all antidepressants are more effective than no
treatment, no class of antidepressants can yet be clearly
shown to be superior to another in research settings,
where compliance considerations are better controlled.
IMPORTANCE OF
ADEQUATE DOSAGE
Maintenance assessments from the 1970s routinely
used a study design that lowered the dosage when the
maintenance phase was reached (e.g., Prien et al.,
1973). While virtually all such studies still showed that
active medication maintenance was superior to pla-
cebo treatment—even after doses were lowered from
those used during acute treatment—the results almost
certainly would have been more impressive if investi-
gators had employed full dosages of antidepressant
medications during the maintenance phase. The dose
of antidepressant needed for long-term maintenance
has been addressed by Frank (1993) and Montgomery
(1997), with the conclusion that the full antidepressant
doses are needed for long-term treatment. Until any
agent is shown to have equal effectiveness at lower
doses, it should be assumed that full antidepressant
doses (“whatever was required to end the acute epi-
sode”) are needed for long-term treatment for all anti-
depressants (Montgomery, 1997).
IMPACT OF COMBINATIONS AND
MEDICATION “SWITCHES”
Few studies have evaluated the combination of
TCAs and psychotherapy (Frank et al., 1990), and no
long-term standardized assessments have compared
combinations of SSRIs and psychotherapy with SSRIs
alone. The efficacy of combination drug therapy vs.
drug monotherapy also is poorly studied (Almatura
and Percudani, 1993). Similarly, anecdotal reports ac-
tually suggest that “switches” may lead to a greater
risk of relapse and that the transition can often be a
difficult time. While the absence of standardized stud-
ies makes generalizations risky, it is prudent to assume
that the antidepressant that produces remission in the
short term generally should be continued during
maintenance. If the caveat of “let the switcher beware”
is accepted, the clinician should consider “long-term”
or “maintenance” aspects at the time of writing the
first prescription, obviously choosing an agent that is
believed to resolve not only the acute episode but will
be safe, well tolerated, associated with maximal com-
pliance, and effective in maintaining euthymia over an





Current selection criteria for maintenance antide-
pressant treatment are summarized in Table 2. Per-
haps the best accepted criterion is that individuals
with three or more documented episodes of MDD are
recommended for indefinite treatment with antide-
pressant medications, with the rationale being that the
majority of those with multiple episodes appear to
have another episode within one to two years unless
maintenance treatment is continued (summarized in
Greden, in press). Other criteria are less well substan-
tiated and rely upon clinical, genetic or laboratory fea-
tures. These features include patients with a strong
family history of mood disorders; a prior episode of
profound severity; prior suicidal behavior; prior psy-
chosis; prior documented relapse following treatment
discontinuation; prior demonstrated treatment refrac-
toriness and chronicity; and coexisting medical prob-
lems or complications of aging that would make
another episode hazardous. Some data suggest that if
the “first episode” occurred when the patient was
Research Article: Extended Antidepressant Maintenance 47
older, the risk of relapse is higher without mainte-
nance treatment (Grof et al., 1973; Zis and Goodwin,
1979), but these observations may be confounded by
unrecorded prior episodes or those with mild severity
that did not meet diagnostic criteria for MDD. Pa-
tients who have had abnormal hypothalamic-pituitary
adrenal dysregulation that fails to normalize despite im-
provement in symptoms also appear at higher risk for
prompt relapse if treatment is discontinued (Greden et
al., 1983; Ribeiro et al., 1993).
ATTENUATION OF RESPONSE
TO MAINTENANCE TREATMENT
Systematic controlled maintenance studies have not
been conducted for longer than five years, so it cannot
be definitively stated that beneficial effects remain in-
definitely. Nevertheless, clinical experience with TCAs
suggests that euthymia may be successfully maintained
for decades. Some anecdotal reports have suggested
that the initial clinical response to an SSRI may fade
with time, possibly with a subsequent relapse (Gold-
berg et al., 1995), but lacking well-controlled studies
this observation remains in question. Fava (1995) ob-
served that patients may improve with higher or lower
doses, different SSRIs, supplementation with TCAs, or
adjuvant agents such as lithium or psychostimulants.
However, such recovery may also be transient. Confir-
mation of this possible attenuation pattern requires fur-
ther study. Should attenuation exist, effective clinical
interventions need to be sought (Goldberg et al., 1995).
RISK–BENEFIT RATIO
The risk–benefit ratio for extended antidepressant
maintenance treatment appears favorable. Studies to
date have not shown any major long-term medical
complications to be associated with maintenance use
of TCAs, SSRIs, or other antidepressants, with the
exception of long-term lithium treatment, which can
induce distal renal tubular fibrosis in a small per-
centage of users. Clinicians must continue to be alert
to possible deleterious consequences that might de-
velop after years of treatment (including assessment of
the question of whether extended antidepressant
maintenance treatment might induce neurobiological
changes that actually increase the likelihood of relapse
if medications are ever discontinued). Since our expe-
rience base is already vast, long-term adverse manifes-
tations seem unlikely. In comparison, the risks of
treatment discontinuation are well documented and
serious. Repeat episodes of depression cost lives, de-
stroy function, and are grossly expensive to society.
Recurrence should be prevented whenever possible.
COMPLIANCE: A VARIABLE IN
MAINTENANCE TREATMENT
A requisite for effective maintenance of euthymia is
that the patient must take the medication prescribed.
The ideal medication would thus have well-established
efficacy, high safety profile, few or no troubling side
effects, few drug–drug interactions (and none that
present major safety considerations), demonstrated
long-term effectiveness, simplicity of use, and clear
cost-effectiveness (Mendels, 1992; Preskorn, 1995).
While no current antidepressant completely fulfills this
idealized check list, there are important differences
among antidepressant classes. Tricyclics have demon-
strated acute efficacy and long-term effectiveness but
are notable for their preponderance of major adverse
events, some of which can be life-threatening, espe-
cially among elderly patients (e.g., cardiac arrhythmias
or orthostatic hypotension, with falls and fractures).
TCAs also have lethal suicide potential and they pro-
duce an array of unpleasant side effects (dry mouth, se-
dation, weight gain, blurry vision, urinary hesitancy,
lethargy) that make long-term use difficult.
COMPLIANCE AND
TOLERABILITY OF SSRIS VS.
TCAS AND HETEROCYCLICS
The paucity of life-threatening or troublesome anti-
cholinergic side effects for the SSRIs largely explains
why they have become “first-line” agents, although
their greater effectiveness in patients with atypical de-
pression or those with selected comorbid syndromes
such as depression and obsessive-compulsive disorder
TABLE 2. Indications for extended maintenance antidepressants: patient characteristics
Genetic history
Number of prior episodes (1) Clinical features (2) or laboratory data (3)
Three or more prior episodes of MDD
One or two prior episodes of MDD Prior suicidal behavior Positive family history
coupled with columns two or three Treatment refractoriness of mood disorders
Psychosis Persistent HPA
Concurrent medical, personal or occupational dysregulation
circumstances that make future episodes “hazardous”
Prompt relapse following prior discontinuation of treatment
Chronic dysthymia coupled with: MDD (“Double Depression”)
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also has contributed to their higher acceptance. While
the more favorable side effect and safety profile of
SSRIs make them more “user-friendly” for physicians,
of greater relevance for maintenance is the fact they
appear to result in higher compliance among patients.
For example, Montgomery et al. (1994) conducted a
meta-analysis of 42 published randomized control tri-
als investigating the discontinuation rates of the TCAs
and SSRIs, whether motivated by side effects or per-
ceived lack of efficacy. Stoppage rates were similar for
lack of efficacy, but discontinuation rates for side ef-
fect reasons were significantly greater for TCAs (P
<0.01). The authors concluded that SSRIs are favored
as first-line treatments primarily because of better tol-
erability and less toxicity. Schatzberg (1997) reviewed
16 controlled studies of SSRIs in severe depression
and concluded that SSRIs are superior to placebo and
as effective but better tolerated than TCAs. Anderson
and Tomenson (1995) also concluded that SSRIs were
better tolerated than TCAs as measured by side effect
dropout rates but were not convinced the differences
were clinically or economically relevant. Hotopf et al.
(1997) studied the discontinuation rates of SSRIs,
older and newer TCAs, and heterocyclic antidepres-
sants and concluded that the SSRI discontinuation
rates were not significantly different from the hetero-
cyclic compounds or the newer TCAs and recom-
mended tricyclics as the first-line medication. This
topic requires further study.
STRATEGIES FOR ENHANCING
COMPLIANCE
Even with the most favorable agents, compliance
rates with antidepressants are disturbingly low for
most patients treated for depression. The nature of
this disease is that it seems to discourage many pa-
tients from seeking or sustaining treatment. Thus,
physicians and associated members of the treatment
team must work diligently to enhance compliance.
Table 3 lists clinical recommendations for antidepres-
sant maintenance medications. A number of new tech-
nological innovations have been introduced that may
aid in this task during future years. One example is the
use of computerized “memory caps” for the medica-
tion bottle, with each cap containing digital time and
date windows that change whenever the cap is re-
moved. The cap provides a visual reminder to the pa-
tient of the time of the last dosage. The caps, when
linked to a computer via a modem, also generate com-
puterized printouts that illustrate compliance and this
information can be used to identify patterns (e.g.,
skipping doses on weekends) and provide opportuni-
ties to reemphasize the importance of adherence to
recommended timetables. Such innovations may be
especially helpful with cognitively impaired patients.
Another example of future technology is the use of the
TABLE 3. Clinical recommendations for
antidepressant maintenance medications
“Full-dose” for all agents
Choose a medication with favorable side effect and safety profiles at
the time treatment is started
Educate patient and family about plans for extended treatment at
commencement of acute treatment
Avoid “switches” of agents if at all possible
If “switches” necessary, a different “class” of medication is
preferable
Self-rating scales at each visit
Patient graphs and diaries to monitor linkage between symptom
severity and medication dosage
No “drug holidays”
Family involvement, close monitoring, and technological aids to
promote compliance
Dosage adjustment if severity worsens or during high-risk times
personal digital assistant or “PDA” (hand-held com-
puters) that provide the patient with self-tailored mes-
sages designed to encourage compliance. Different
tailored messages might be conveyed depending on
the data inserted (e.g. concern about weight gain) and
the trends identified. Such technologies need to be
studied systematically to determine their effectiveness
and economic considerations and availability will need
to be improved, but predictably these and other future
innovations will help enhance compliance. Meanwhile,
the physician’s emphasis on educating the patient and
family at the time of the first prescription, close physi-
cian monitoring during each appointment, early and
repeated use of charts and graphs, use of diaries that
incorporate medication times, and encouragement for
the patient and family to become involved in patient
advocacy groups, such as the National Depression and
Manic Depressive Association and the National Alli-
ance for the Mentally Ill, are important strategies to





For many patients with depression and high risk of
relapse, continued maintenance medications appear to
be the preferred course (Greden, 1993; Greden, in
press). For those circumstances when discontinuation
seems inevitable or unavoidable (impending elective
surgeries, patient refuses to continue, etc.), the half-life
of the medication should be taken into account when
planning discontinuation. If feasible, a downward taper
of dosage should be scheduled. The optimal time pe-
riod of this taper continues to be a topic of debate and
requires further study but several weeks appear to be
the minimum for agents with a shorter half-life, and
Greden has encouraged tapering over 6–12 months
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(Greden, 1993). While unusual, this long-term taper
prevents discontinuation symptoms, enables adaptation
at the receptor level, and allows earlier recognition and
treatment of “recurrence symptoms” without the devel-





Despite efforts to enhance compliance and sustain
extended maintenance for those patients at high risk
for relapse, some patients will discontinue their anti-
depressant medications. What are the clinical manifes-
tations associated with this event?
The earliest reports of tricyclic antidepressant with-
drawal symptoms were noted soon after the release of
tricyclic agents (Kuhn, 1957; Mann and MacPherson,
1959; Andersen and Kristiansen, 1959). Because TCAs
impact cholinergic, histaminergic, serotonergic, and
adrenergic networks, it was not surprising that discon-
tinuation was associated with a montage of withdrawal
symptoms, including nausea, anorexia, emesis, anxiety,
agitation, insomnia, restlessness, paresthesias, my-
algias, rhinorrhea, diarrhea, and diaphoresis. This
“TCA Withdrawal Syndrome” was described in detail
by Dilsaver and Greden (1984). Central and periph-
eral cholinergic overdrive were postulated to be the
etiology of many of the symptoms, supported by the
observation that most symptoms responded favorably
to both anticholinergic administration or resumption
of the medication (Dilsaver et al., 1983; Dilsaver and
Greden, 1984; Dilsaver, 1994).
Most SSRIs have also been noted to have with-
drawal symptoms upon sudden discontinuation. Table
4 lists SSRI withdrawal case reports in the literature.
Paroxetine is cited a bit more frequently in withdrawal
case reports than sertraline, while fluoxetine has the
fewest citations. The SSRI withdrawal symptoms
noted upon discontinuance or decrease in dose have
some overlap in symptom profile with TCAs, but
some relatively unique “CNS-like” symptoms have
been noted that seem to differ somewhat from the
TCA withdrawal profile. The most common of these
include dizziness, lightheadedness, vertigo, electric
shock-like sensations, and gait instability. These are
often described as having an acute onset, short dura-
tion, and occurring at multiple times throughout the
day. These CNS-like symptoms have been reported
with all SSRIs. Gastrointestinal withdrawal symptoms
of nausea, emesis, abdominal cramps, and abdominal
distention were frequently reported with paroxetine
and, occasionally, with sertraline. Other SSRI with-
drawal symptoms also occur (see Table 4 for refer-
ences). A retrospective chart review of 352 patients
(Coupland et al., 1996) and a comparison of post-mar-
keting safety in the United Kingdom (Price et al.,
1996) confirm this diffuse profile. Symptoms usually
occurred one to three days after dose decrease or dis-
continuation of the drug and commonly resolved
within ten days.
Few standardized comparisons of withdrawal
symptoms among SSRI agents exist. The Committee
on Safety of Medicines (CSM), which advises the
Medicines Control Agency (MCA), the UK health au-
thority, reported that insomnia, tremor, dizziness,
sweating, nausea, and confusion appear to be more
common upon withdrawal of paroxetine than with
other SSRIs (Anon, 1993). However, the Drug Safety
Research Unit (DSRU) in Southhampton, UK, found
no difference in recorded events occurring within
seven days of discontinuation of either paroxetine or
the other SSRI agents (Choo, 1993; Inman et al.,
1993). A recent study (Blomgren et al., 1997) com-
pared discontinuation-emergent signs among patients
stopping fluoxetine, paroxetine, and sertraline. The
five most common symptoms found were dizziness,
nausea, insomnia, headache, and nervousness. Brief in-
terruptions in paroxetine and sertraline produced
more adverse effects than fluoxetine, with differences
presumably attributable to the long half-life of flu-
oxetine. This is in accordance with Price’s observation
that the number of withdrawal symptoms reported is
greatest with paroxetine and least with fluoxetine
(Price et al., 1996). Paroxetine’s short half-life and
TABLE 4. SSRI withdrawal case reports
Author/year Drug(s)
Cooper, 1988 Fluoxetine
Stoukides and Stoukides, 1991 Fluoxetine
Szabadi, 1992 Fluvoxamine
Barr et al., 1994 Paroxetine
Ellison, 1994 Fluoxetine, sertraline,
paroxetine
Keuthen et al., 1994 Paroxetine
Lauterbach, 1994 Fluoxetine
Louie et al., 1994 Sertraline
Kasantikul, 1995 Fluoxetine
Bloch et al., 1995 Paroxetine
Debattista and Schatzberg, 1995 Paroxetine
Dominguez and Goodnick, 1995 Paroxetine
Einbinder, 1995 Fluoxetine
Fava and Grandi, 1995 Paroxetine, sertraline
Frost and Lal, 1995 Paroxetine, sertraline
Koopowitz and Berk, 1995 Paroxetine
Leiter et al., 1995 Sertraline
Phillips, 1995 Paroxetine, sertraline
Pyke, 1995 Paroxetine
Amsden and Georgian, 1996 Sertraline
Berlin, 1996 Fluoxetine
Bhuamik and Wildgust, 1996 Paroxetine
Pacheco et al., 1996 Paroxetine
Reeves and Pinkofsky, 1996 Paroxetine
Rosenstock, 1996 Sertraline
Landry and Roy, 1997 Paroxetine
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high receptor specificity are postulated to be respon-
sible for these events. The hypothesized role of sero-
tonin in coordinating sensory and autonomic function
with motor activity has been proposed as a possible
mechanism accounting in part for these CNS-like dis-
continuation symptoms (Coupland et al., 1996; Jacobs
and Fornal, 1993).
Several case reports describe withdrawal symptoms
with venlafaxine (Farah and Lauer, 1996; Giakas and
Davis, 1997; Louie et al., 1996). Symptoms included
the familiar profile of dizziness, headaches, nausea,
fatigue, shock-like sensations, and gastrointestinal
problems. One report for trazodone withdrawal exists
(Otani et al., 1994). No reports of mirtazapine, nefazo-
done, or bupropion withdrawal have yet been pub-
lished. MAOI withdrawal reportedly may result in
severe anxiety, agitation, insomnia or drowsiness, pres-
sured speech, hallucinations, cognitive impairment,
delirium, suicidality, and delusions of persecution
(Dilsaver, 1994). In summary, withdrawal manifesta-
tions are likely following the discontinuation of most
antidepressants that have half-lives ranging from hours
to several days, but symptom constellations and sever-




Treatment of antidepressant withdrawal symptoms
has not been systematically studied. For TCAs, anti-
cholinergic medications relieve most manifestations
(Dilsaver and Greden, 1984). The TCA can also be
restarted and tapered over a longer time period. For
SSRI discontinuation symptoms, the agent can also be
restarted. Reports confirm, for example, that the re-
sumption of paroxetine (Koopowitz and Berk, 1995;
Debattista and Schatzberg, 1995; Phillips, 1995; Do-
minguez and Goodnick, 1995) resulted in the prompt
resolution of symptoms. Meclizine (25 mg/day) or di-
menhydrinate (50 mg/day) (Pyke, 1995) have been
prescribed in attempts to control dizziness, and cycli-
zine (dose unknown) (Koopowitz and Berk, 1995) has
been used to alleviate nausea following the discontinu-
ation of paroxetine. Prevention of discontinuation
syndromes through gradual taper continues to be the
preferred option.
While generally not life-threatening, antidepressant
discontinuation syndromes may be frightening to the
patient, impair quality of life, and prompt the patient
to believe that depressive symptoms are returning or to
fear that “addiction,” dependency, or a serious illness
may have developed. Work performance, driving skills,
and routine activities may be significantly altered.
Thus, discontinuation symptoms should not be ig-
nored. Patients should be educated at the outset of
treatment about the potential for withdrawal symptoms
and encouraged to avoid sudden discontinuations.
CONCLUSION
While acute episodes of depression are under-rec-
ognized and under-treated (Hirschfeld et al., 1997), it
can be argued that the neglect of maintenance treat-
ment of depression is of equal or greater importance.
The public health and fiscal consequences for multiple
recurrences are profound. Whatever the reasons for
past neglect, maintenance requires future prioritiza-
tion. Physicians not only have well-accepted, powerful
medicinal agents for alleviating acute episodes of de-
pression, for most patients they also have powerful
tools for maintaining euthymia. Greater use of these
tools appears warranted.
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